| MORPHOSYS AG O.N. | 82.70 / +0.85% |
| Date/Time | 03/05 / 15:11 |
| Chg. / Chg.(%) | 0.70 / +0.85% |
| Bid | - |
| Ask | - |
| Open | 81.02 |
| Previous Close | 82.00 |
| High | 82.70 |
| Low | 81.02 |
| Volume [EUR] | 3,225.30 |
| Volume [Units] | 39 |
| Price fixings | 2 |
| ISIN | DE0006632003 |
| Security | MOR |
| Exchange | Hannover |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| Lang & Schwa.. | 81.680 |  |
|
| Xetra | 81.60 | |
125,971 |
| Turquoise | 81.28 |  |
28,873 |
| Cboe Europe .. | 81.60 | |
25,487 |
| TradeGate | 82.200 |  |
14,639 |
| London Inter.. | 81.80 | |
9,898 |
| Stuttgart | 81.740 | |
857 |
| Frankfurt | 81.6800 | |
677 |
| gettex | 81.740 | |
515 |
| Cboe Europe .. | 82.95 | |
110 |
| Cboe Europe .. | 82.90 | |
106 |
| München | 81.68 | |
72 |
| Düsseldorf | 81.52 | |
66 |
| Hannover | 82.70 | |
39 |
| Berlin | 82.00 | |
25 |
| Hamburg | 82.62 | |
20 |
| Vienna Globa.. | 81.78 | |
0 |
| Nasdaq Other.. | 113.1500 | 100 | |
| EUREX | Options | ||
News
- I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Multiple Myeloma in Mainland China
04/27/2020 / 22:01 - GlobeNewswire - MOR106 clinical development in atopic dermatitis stopped for futility
10/28/2019 / 21:45 - GlobeNewswire - Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
04/23/2019 / 22:02 - GlobeNewswire - Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
04/23/2019 / 22:01 - GlobeNewswire - Genmab Announces that the Patent Infringement Lawsuit Relating to DARZALEX® is Over
01/31/2019 / 13:36 - GlobeNewswire
Real-time